Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1

Andrew Fesler; Hua Liu; Jingfang Ju

doi:10.18632/oncotarget.23414

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1

Andrew Fesler, Hua Liu and Jingfang Ju _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:2367-2383. https://doi.org/10.18632/oncotarget.23414

Metrics: PDF 2348 views | HTML 3520 views | ?

Abstract

Andrew Fesler1, Hua Liu1 and Jingfang Ju1

1Department of Pathology, School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA

Correspondence to:

Jingfang Ju, email: [email protected]

Keywords: 5-fluorouracil; miR-15a; colorectal cancer; chemoresistance; modified miRNA

Abbreviations: CSC, colon cancer stem cells; CLL, chronic lymphocytic leukemia; TCGA, The Cancer Genome Atlas; TS, thymidylate synthase

Received: October 10, 2017 Accepted: December 08, 2017 Published: December 19, 2017

ABSTRACT

Despite advances in colon cancer treatments, resistance and recurrence remain a significant challenge in treating patients. Novel therapeutic strategies are in urgent need to overcome resistance and improve patient outcomes. MicroRNA based therapeutics have potential to help combat resistance. In this study, we have shown that low miR-15a expression correlates with poor patient prognosis. We have demonstrated the therapeutic potential of miR-15a in colon cancer. miR-15a inhibits several important genes (BCL2, BMI1, YAP1 and DCLK1), decreasing cancer progression and resistance. Additionally, by replacing uracil in miR-15a with 5-fluorouracil, we created a novel miR-15a mimic with enhanced therapeutic potential. This mimic maintains target specificity and is more potent than unmodified miR-15a in vitro and inhibits colon tumor metastasis in vivo. This mimic has great potential for therapeutic development for treating colon cancer patients. This novel modification has potential to advance the development of other microRNA based therapeutics beyond miR-15a.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23414

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1

Abstract